{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:12:01Z","timestamp":1790766721281,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T00:00:00Z","timestamp":1631664000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ijid.2021.09.028","type":"journal-article","created":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T01:00:04Z","timestamp":1632099604000},"page":"189-194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Characterizing the gene mutations associated with resistance to gatifloxacin in Mycobacterium tuberculosis through whole-genome sequencing"],"prefix":"10.1016","volume":"112","author":[{"given":"Jing","family":"Bi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangdong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanjuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoqin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yicheng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2021.09.028_bib0001","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1128\/AAC.46.4.1022-1025.2002","article-title":"In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis","volume":"46","author":"Alvirez-Freites","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2021.09.028_bib0002","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1128\/AAC.50.1.104-112.2006","article-title":"Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes","volume":"50","author":"Aubry","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2021.09.028_bib0003","series-title":"Mycobacteria protocols","first-page":"1","article-title":"Whole-genome sequencing for comparative genomics and de novo genome assembly","author":"Benjak","year":"2015"},{"key":"10.1016\/j.ijid.2021.09.028_bib0004","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1517\/13543784.11.2.233","article-title":"Fluoroquinolones and tuberculosis","volume":"11","author":"Bryskier","year":"2002","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ijid.2021.09.028_bib0005","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1093\/jac\/dkx316","article-title":"Identification of novel mutations associated with cycloserine resistance in Mycobacterium tuberculosis","volume":"72","author":"Chen","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2021.09.028_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1574-695X.2011.00831.x","article-title":"Efflux as a mechanism for drug resistance in Mycobacterium tuberculosis","volume":"63","author":"da Silva","year":"2011","journal-title":"FEMS Immunol Med Microbiol"},{"key":"10.1016\/j.ijid.2021.09.028_bib0007","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.3389\/fimmu.2017.01134","article-title":"What have we learnt about BCG vaccination in the last 20\u2009years?","volume":"8","author":"Dockrell","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.ijid.2021.09.028_bib0008","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1128\/AAC.00541-09","article-title":"Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam","volume":"53","author":"Duong","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2021.09.028_bib0009","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1159\/000109769","article-title":"Importance of the efflux pump systems in the resistance of Mycobacterium tuberculosis to fluoroquinolones and linezolid","volume":"53","author":"Escribano","year":"2007","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ijid.2021.09.028_bib0010","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02308-2016","article-title":"World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update","volume":"49","author":"Falzon","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijid.2021.09.028_bib0011","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/jac\/44.3.393","article-title":"Activity of moxifloxacin against mycobacteria","volume":"44","author":"Gillespie","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2021.09.028_bib0012","first-page":"265","article-title":"Fluoroquinolones: a new treatment for tuberculosis?","volume":"2","author":"Gillespie","year":"1998","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijid.2021.09.028_bib0013","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S1473-3099(03)00671-6","article-title":"Fluoroquinolones, tuberculosis, and resistance","volume":"3","author":"Ginsburg","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2021.09.028_bib0014","series-title":"Quinolone antimicrobial agents","author":"Hooper","year":"2003"},{"key":"10.1016\/j.ijid.2021.09.028_bib0015","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1128\/AAC.47.2.653-657.2003","article-title":"Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis","volume":"47","author":"Hu","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2021.09.028_bib0016","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.3390\/app10062153","article-title":"Drug-resistant tuberculosis 2020: where we stand","volume":"10","author":"Iacobino","year":"2020","journal-title":"Appl Sci"},{"key":"10.1016\/j.ijid.2021.09.028_bib0017","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1128\/AAC.42.8.2066","article-title":"In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis","volume":"42","author":"Ji","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2021.09.028_bib0018","first-page":"605","article-title":"Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis","volume":"10","author":"Johnson","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijid.2021.09.028_bib0019","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1038\/emi.2014.21","article-title":"Association of gyrA\/B mutations and resistance levels to fluoroquinolones in clinical isolates of Mycobacterium tuberculosis","volume":"3","author":"Li","year":"2014","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.ijid.2021.09.028_bib0020","doi-asserted-by":"crossref","first-page":"e58664","DOI":"10.1371\/journal.pone.0058664","article-title":"Aggressive regimens for multidrug-resistant tuberculosis decrease all-cause mortality","volume":"8","author":"Mitnick","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2021.09.028_bib0021","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1128\/AAC.43.1.85","article-title":"Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis","volume":"43","author":"Miyazaki","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2021.09.028_bib0022","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.2165\/00003495-200767140-00007","article-title":"Fluoroquinolones for the treatment of pulmonary tuberculosis","volume":"67","author":"Moadebi","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.ijid.2021.09.028_bib0023","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1099\/jmm.0.046821-0","article-title":"Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin","volume":"62","author":"Nosova","year":"2013","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.ijid.2021.09.028_bib0024","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1164\/rccm.200310-1380OC","article-title":"Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis","volume":"169","author":"Nuermberger","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijid.2021.09.028_bib0025","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1164\/rccm.200407-885OC","article-title":"Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis","volume":"170","author":"Nuermberger","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijid.2021.09.028_bib0026","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1128\/AAC.06272-11","article-title":"Extending the definition of the GyrB quinolone resistance-determining region in Mycobacterium tuberculosis DNA gyrase for assessing fluoroquinolone resistance in M. tuberculosis","volume":"56","author":"Pantel","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2021.09.028_bib0027","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1093\/jac\/dkz150","article-title":"Characterization of linezolid-resistance-associated mutations in Mycobacterium tuberculosis through WGS","volume":"74","author":"Pi","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2021.09.028_bib0028","doi-asserted-by":"crossref","first-page":"e12245","DOI":"10.1371\/journal.pone.0012245","article-title":"Structural insights into the quinolone resistance mechanism of Mycobacterium tuberculosis DNA gyrase","volume":"5","author":"Piton","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2021.09.028_bib0029","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s40265-018-1043-y","article-title":"The role of fluoroquinolones in the treatment of tuberculosis in 2019","volume":"79","author":"Pranger","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ijid.2021.09.028_bib0030","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S0924-8579(02)00239-X","article-title":"In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis","volume":"20","author":"Rodr\u00edguez","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijid.2021.09.028_bib0031","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1586\/14787210.2015.1021784","article-title":"Pyrazinamide: the importance of uncovering the mechanisms of action in mycobacteria","volume":"13","author":"Stehr","year":"2015","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijid.2021.09.028_bib0032","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1179\/joc.2005.17.2.169","article-title":"In vitro activity of fluoroquinolones against Mycobacterium tuberculosis","volume":"17","author":"Sulochana","year":"2005","journal-title":"J Chemother"},{"key":"10.1016\/j.ijid.2021.09.028_bib0033","doi-asserted-by":"crossref","first-page":"227","DOI":"10.4236\/jtr.2018.63021","article-title":"gyrA gene mutation conferring phenotypic cross-resistance among fluoroquinolones (ofloxacin, levofloxacin and gatifloxacin) in multidrug resistant Mycobacterium tuberculosis strains isolated from pulmonary MDR-TB patients in Bangladesh","volume":"6","author":"Tasnim","year":"2018","journal-title":"J Tuberc Res"},{"key":"10.1016\/j.ijid.2021.09.028_bib0034","doi-asserted-by":"crossref","first-page":"5427","DOI":"10.1128\/AAC.00662-15","article-title":"Correlation between GyrA substitutions and ofloxacin, levofloxacin, and moxifloxacin cross-resistance in Mycobacterium tuberculosis","volume":"59","author":"Willby","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2021.09.028_bib0035","unstructured":"World Health Organization. Global tuberculosis report 2019. Geneva: WHO; 2019."},{"key":"10.1016\/j.ijid.2021.09.028_bib0036","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1093\/jac\/dkv150","article-title":"Identification of novel mutations associated with clofazimine resistance in Mycobacterium tuberculosis","volume":"70","author":"Zhang","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2021.09.028_bib0037","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188181","article-title":"Single molecule sequencing of the M13 virus genome without amplification","volume":"12","author":"Zhao","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2021.09.028_bib0038","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004795.pub3","article-title":"Fluoroquinolones for treating tuberculosis","volume":"1","author":"Ziganshina","year":"2008","journal-title":"Cochrane Database Syst Rev"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971221007359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971221007359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:02:22Z","timestamp":1761120142000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971221007359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":38,"alternative-id":["S1201971221007359"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2021.09.028","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterizing the gene mutations associated with resistance to gatifloxacin in Mycobacterium tuberculosis through whole-genome sequencing","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2021.09.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}